logo
UK's most commonly prescribed drug cuts risk of dementia, study suggests

UK's most commonly prescribed drug cuts risk of dementia, study suggests

Independent05-04-2025

A common drug prescribed to help lower cholesterol levels has been found to cut dementia risk.
High cholesterol has long been linked to general poor health, but a recent study published in the Journal of Neurology and Psychiatry revealed it may also increase the risk of dementia.
It found people with lower levels of 'bad cholesterol' in their blood are less likely to develop the memory robbing condition.
The study suggested that cholesterol-lowering statins, the most commonly prescribed drugs in the UK, also offered a boost in protection against dementia.
Cholesterol is a natural fatty substance found in the blood. Low-density lipoproteins (LDL) also known as 'bad cholesterol' can raise the risk of a heart attack or stroke if they are too high.
But exercising and eating healthily can bring these levels down. Drugs called statins, which are given to around 8 million Britons, are also prescribed to those with high cholesterol if lifestyle changes are not enough, helping to prevent cardiovascular event.
However, researchers from Hallym University College of Medicine in South Korea claimed the drug could also protect against dementia.
The scientists analysed data collected by 11 university hospitals which followed adults for 180 days after they got their cholesterol levels tested and observed whether the patients went on to develop dementia in the study period.
Researchers identified 192,213 people with LDL levels less than 1.8 mmol/L and 379,006 patients with LDL levels more than 3.4 mmol/L.
Those with lower LDL levels were 26 per cent less likely to be diagnosed with dementia compared with those who had higher cholesterol levels.
These patients were also 28 per cent less likely to be diagnosed with Alzheimer's disease.
However, if LDL levels dropped below 1.4 mmol/L, participants only had an 18 per cent lower risk of getting dementia or Alzheimer's.
Plus, when LDL levels dipped below 0.8 mmol/L, the protective effect disappeared entirely.
Researchers found the drug statins did boost protection against dementia, even when participants LDL levels were already on the lower side.
For those below 1.8 mmol/L, dementia risk was reduced by 13 per cent and Alzheimer' by 12 per cent in comparison to those who did not take statins.
Dr Julia Dudley, Head of Research at Alzheimer's Research UK says: 'High levels of LDL cholesterol were identified as a risk factor for dementia in last year's Lancet Commission on dementia prevention.'
'The use of statins seemed to offer a protective effect – even in those who already had cholesterol levels within a lower range,' she added.
'However, dementia risk is complex and influenced by many factors. Without a detailed picture of what's going on in the brain we do not know if there is a direct link between lower cholesterol and reduced dementia risk.'
Researchers explained that because it was an observational study, no firm conclusions can be drawn about cause and effect.
The authors concluded: 'Low LDL-C levels (<70 mg/dL (<1.8 mmol/L)) are significantly associated with a reduced risk of dementia, including Alzheimer's disease related dementia, with statin therapy providing additional protective effects.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema
Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema

Daily Mirror

time18 hours ago

  • Daily Mirror

Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema

Many of us will be adding it to our Sunday Roast with meat, potatoes and carrots A herb popular in UK dishes and often served at Sunday Dinner has been linked to better brain health, reduced inflammation and improved immune function. Research suggests rosemary may even be able to help in the fight against Alzheimer's disease, the leading cause of dementia worldwide. Rosemary is often served with lamb and added to roast potatoes and carrots on Sundays. It is also a staple herb in Mediterranean meals. ‌ In one study, people who breathed in rosemary's scent performed better on memory tasks compared to those in an unscented environment. ‌ Dipa Kamdar, Senior Lecturer in Pharmacy Practice at Kingston University, said: " There are several mechanisms at play. For starters, rosemary stimulates blood circulation, including to the brain, helping deliver more oxygen and nutrients, which may improve mental clarity. It also has calming properties; some studies suggest its aroma can reduce anxiety and improve sleep. Lower stress can mean better focus and memory retention. "Rosemary contains compounds that interact with the brain's neurotransmitters. One such compound, 1,8-cineole, helps prevent the breakdown of acetylcholine, a brain chemical essential for learning and memory. By preserving acetylcholine, rosemary may help support cognitive performance, especially as we age." She added: " Rosemary is packed with antioxidants, which help protect brain cells from damage caused by oxidative stress – a major factor in cognitive decline. Rosemary is rich in phytochemicals, plant compounds with health-enhancing effects. One of the most powerful is carnosic acid, an antioxidant and anti-inflammatory agent that helps shield brain cells from harm, particularly from the kinds of damage linked to Alzheimer's disease." In a study this year. scientists found a version of carnosic acid appeared to improve memory, boosted the number of synapses (the connections between brain cells), and reduced harmful Alzheimer's related proteins like amyloid-beta and tau. The same compound could be used to treat type 2 diabetes, cardiovascular disease and Parkinson's disease. Dipa told The Conversation: " Rosemary's benefits could extend well beyond the brain. It's been used traditionally to ease digestion, relieve bloating and reduce inflammation. Compounds like rosmarinic acid and ursolic acid are known for their anti-inflammatory effects throughout the body. Rosemary may even benefit the skin – a review suggests it can help soothe acne and eczema, while carnosic acid may offer anti-ageing benefits by protecting skin from sun damage. ‌ " Rosemary oil also has antimicrobial properties, showing promise in food preservation and potential pharmaceutical applications by inhibiting the growth of bacteria and fungi. For most people, rosemary is safe when used in food, teas or aromatherapy. But concentrated doses or extracts can pose risks. Consuming large amounts may cause vomiting or, in rare cases, seizures – particularly in people with epilepsy. "There's also a theoretical risk of rosemary stimulating uterine contractions, so pregnant people should avoid high doses. Because rosemary can interact with some medications – such as blood thinners – it's best to check with a healthcare provider before taking large amounts in supplement form. "Rosemary is more than just a kitchen staple. It's a natural remedy with ancient roots and modern scientific backing. As research continues, particularly into breakthrough compounds like diAcCA, rosemary could play an exciting role in future treatments for Alzheimer's and other chronic conditions. "In the meantime, adding a little rosemary to your life – whether in a meal, a cup of tea, or a breath of its fragrant oil – could be a small step with big health benefits."

Alzheimer's blood test ‘can accurately pick up early symptoms'
Alzheimer's blood test ‘can accurately pick up early symptoms'

North Wales Chronicle

time3 days ago

  • North Wales Chronicle

Alzheimer's blood test ‘can accurately pick up early symptoms'

Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

Alzheimer's blood test ‘can accurately pick up early symptoms'
Alzheimer's blood test ‘can accurately pick up early symptoms'

South Wales Guardian

time3 days ago

  • South Wales Guardian

Alzheimer's blood test ‘can accurately pick up early symptoms'

Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store